-The Telegraph An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy. India’s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government. Clinical Trials in India, Tanzania, and Thailand...
More »SEARCH RESULT
Shamnad Basheer, Intellectual Property Law Professor at NUJS interviewed by V Venkatesan
PROFESSOR Shamnad Basheer joined the National University of Juridical Sciences (NUJS), Kolkata, in November 2008 as the first Ministry of Human Resource Development Chaired Professor in Intellectual Property Law. Before this, he was Frank H. Marks Visiting Associate Professor of Intellectual Property Law at the George Washington University law school and a research associate at the Oxford Intellectual Property Research Centre (OIPRC). He is the founder of several initiatives, including...
More »Question of efficacy -Leena Menghaney
The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »Drug approvals fall on account of tardy & tedious process by NDAC-Divya Rajagopal
Confusion sparked by the setting up of a new committee for drug approvals has led to a slide in the number of new medicines getting cleared even as millions of Indians struggle with diabetes and heart failures remain a major killer. The Drug Controller General of India (DCGI) has shed its role as the sole approver of new drugs in the country after a new committee, set up by the health...
More »